Search Result

Results for "

αvβ5 integrin

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Integrin (15) Akt (1) Autophagy (1) Fluorescent Dye (1) Interleukin Related (1) PI3K (1) Radionuclide-Drug Conjugates (RDCs) (1) TGF-β Receptor (2)
By Research Areas:	Cancer (14) Cardiovascular Disease (3) Endocrinology (1) Infection (2) Inflammation/Immunology (6)

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Targets Recommended: Integrin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16143

Cilengitide TFA Maximum Cited Publications 70 Publications Verification EMD 121974 TFA	Integrin Autophagy	Cancer
Cilengitide is a potent and selective *integrin* inhibitor for α_vβ₃ and α_vβ₅ receptor, with IC₅₀ values of 4 nM and 79 nM, respectively.

HY-15102

MK-0429 5+ Cited Publications L-000845704	Integrin	Inflammation/Immunology Cancer
MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide *pan-integrin* antagonist with IC₅₀ values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1, respectively .

HY-P5133

Synstatin (92-119) 1 Publications Verification SSTN92-119	Integrin	Cancer
Synstatin (92-119) is an inhibitor of αvβ3/αvβ5 integrins and IGF1R with anti-angiogenic, anti-proliferative, antioxidant and anti-tumor activities. Synstatin (92-119) competitively blocks the capture of αvβ3/αvβ5 integrins and IGF1R by syndecan-1, disrupts the formation of the syndecan-1 : integrin : IGF1R ternary complex, inhibits integrin activation and talin-mediated signaling pathways, and blocks VEGF-induced angiogenesis. Synstatin (92-119) is applicable to research related to cancer and hepatocellular carcinoma .

HY-19767

GSK 3008348 2 Publications Verification	Integrin TGF-β Receptor	Infection Inflammation/Immunology Cancer
GSK 3008348 is a small molecule antagonist of integrin αvβ6 with IC₅₀ values for αvβ6, αvβ1, αvβ3, αvβ5, and αvβ8 are 1.50, 2.83, 12.53, 4.00, and 2.26 nM, respectively. GSK 3008348 can target the αvβ6 integrin, inhibit TGF-β activation, and thereby alleviate the fibrotic process. GSK 3008348 prevents the binding of the foot-and-mouth disease virus (FMDV) to the αvβ6 integrin receptor on the surface of host cells, thereby inhibiting the entry of the virus. GSK 3008348 can be used for research on pulmonary fibrosis and various types of cancer .

HY-145363

*αvβ5 integrin-IN-1* 1 Publications Verification	Integrin	Cancer
αvβ5 integrin-IN-1 (Compound 12) is a selective αvβ5 inhibitor (pIC₅₀ = 8.2). αvβ5 integrin-IN-1 exhibits 800-fold selectivity for αvβ5 versus αvβ3 .

HY-19307

SB-273005	Integrin Interleukin Related	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
SB-273005 is an orally active non-peptide αvβ3 integrin antagonist with K_i values of 1.2 nM and 0.3 nM for αvβ3 and αvβ5, respectively. SB-273005 blocks the binding of integrins to the RGD sequence in the extracellular matrix. SB-273005 inhibits Rictor phosphorylation and reduces IL-10 secretion. SB-273005 inhibits inflammation, prevents bone loss, regulates vascular smooth muscle function, and reverses pregnancy-induced immune deviation. SB-273005 can be used in the study of rheumatoid arthritis, osteoporosis, and aneurysms. .

HY-130119

Integrin-IN-2	Integrin	Cancer
Integrin-IN-2 (compound 39) is an orally bioavailable pan αv integrin inhibitor. Integrin-IN-2 can increases the αvβ6, αvβ3, αvβ5 and αvβ8 binding affinities with pIC₅₀ values of 7.8, 8.4, 8.4 and 7.4, respectively .

HY-P0295

Gly-Arg-Gly-Asp-Ser GRGDS	Integrin	Others
Gly-Arg-Gly-Asp-Ser (GRGDS) is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC₅₀ of ～5 and ～6.5 μM

HY-19767A

GSK 3008348 hydrochloride 2 Publications Verification	Integrin TGF-β Receptor	Infection Inflammation/Immunology Cancer
GSK 3008348 hydrochloride is a small molecule antagonist of integrin αvβ6 with IC₅₀ values for αvβ6, αvβ1, αvβ3, αvβ5, and αvβ8 are 1.50, 2.83, 12.53, 4.00, and 2.26 nM, respectively. GSK 3008348 hydrochloride can target the αvβ6 integrin, inhibit TGF-β activation, and thereby alleviate the fibrotic process. GSK 3008348 hydrochloride prevents the binding of the foot-and-mouth disease virus (FMDV) to the αvβ6 integrin receptor on the surface of host cells, thereby inhibiting the entry of the virus. GSK 3008348 hydrochloride can be used for research on pulmonary fibrosis and various types of cancer .

HY-19306

SB-267268	Integrin	Cancer
SB-267268 is a selective and nonpeptidic alpha(v)beta3 (αvβ3) and alpha(v)beta5 (αvβ5) integrins antagonist, with K_is of 0.9, 0.5 and 0.7 nM for human αvβ3, monkey αvβ3 and human αvβ5, respectively. SB-267268 inhibits human and mouse αvβ3 with IC₅₀s of 0.68 and 0.29 nM, respectively. SB-267268 reduces angiogenesis and VEGF expression .

HY-D2439

RGD-PEG-Cy3	Fluorescent Dye	Cancer
RGD-PEG-Cy3 is a fluorescent labeling reagent that combines Cy3 fluorescent dye, peptide (RGD) and polyethylene glycol (PEG). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. RGD is a peptide sequence (CRGDKGPDCiRGD) that binds to αvβ3 and αvβ5 integrin receptors on tumor neovasculogenesis to achieve specific tumor tissue targeting .

HY-P2153

Maraciclatide	Integrin	Inflammation/Immunology Cancer
Maraciclatide is a synthetic molecule that binds with high affinity to α_vβ₃ and α_vβ₅ integrins via the RGD peptide. Maraciclatide can be used to detect bone metastasis, breast tumors, vascular disease and rheumatoid arthritis in animal models. Maraciclatide can be studied in research on angiogenesis and inflammation .

HY-P10320

T3 Peptide Tumstatin (69-88), human	PI3K Akt	Cardiovascular Disease
T3 Peptide is an active fragment of tumstatin. T3 Peptide binds integrin α_vβ₃/α_vβ₅, activates the PI3K/Akt/p70S6K signaling pathway, and thus stimulates the proliferation and migration of rat cardiac fibroblasts .

HY-126402

Arg-Gly-Asp TFA	Integrin	Cancer
Arg-Gly-Asp (RGD) is a synthetic peptide corresponding to the cell adhesion sequence for the integrins αVβ1, αVβ3, αVβ5, αVβ6, αVβ8, α8β1, and α5β1. It is a component of radioligands and peptidomimetics that have been used in the study of integrin expression and activity in vivo.

HY-P0295A

Gly-Arg-Gly-Asp-Ser TFA GRGDS TFA	Integrin	Inflammation/Immunology
Gly-Arg-Gly-Asp-Ser (TFA) is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin . Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC₅₀ of ∼5 and ∼6.5 μM .

HY-P10677

HB-3-20	Integrin	Cancer
HB-3-20 leads to degradation of the cell surface integrin α_Vβ₅. Transglutaminase 2 (TG2) has specificity for HB-3-20 (k_cat/K_M=0.16 μM ^-1min ^-1) .

HY-P3335

SU015 DOTA-RGDfK dimer	Integrin Radionuclide-Drug Conjugates (RDCs)	Cardiovascular Disease Cancer
SU015 (DOTA-RGDfK dimer) is a *Integrin* α_vβ₅ and α_vβ₃ antagonist. SU015 exhibits comparable affinity for α_vβ₅ and α_vβ₃, with relatively higher potency and specificity compared to other integrins. SU015 inhibits α_vβ₃-mediated cell adhesion to fibrinogen, α_vβ₃-mediated adhesion of activated platelets to osteopontin, and α_vβ₅-mediated cell adhesion to vitronectin. SU015 shows potent inhibitory effects on FGF2-induced angiogenesis in the CAM model. SU015 carries a linker arm available for radioisotope conjugation, and acts as a target-specific radioreagent when labeled with ⁹⁰Y (i.e., RP697) or ¹⁷⁷Lu (i.e., RP688). SU015 can be used in studies related to tumor metastasis and tumors .

Cat. No.	Product Name	Type

HY-D2439

RGD-PEG-Cy3	Fluorescent Dyes
RGD-PEG-Cy3 is a fluorescent labeling reagent that combines Cy3 fluorescent dye, peptide (RGD) and polyethylene glycol (PEG). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. RGD is a peptide sequence (CRGDKGPDCiRGD) that binds to αvβ3 and αvβ5 integrin receptors on tumor neovasculogenesis to achieve specific tumor tissue targeting .

RGD-PEG-Cy3

Fluorescent Dyes

RGD-PEG-Cy3 is a fluorescent labeling reagent that combines Cy3 fluorescent dye, peptide (RGD) and polyethylene glycol (PEG). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. RGD is a peptide sequence (CRGDKGPDCiRGD) that binds to αvβ3 and αvβ5 integrin receptors on tumor neovasculogenesis to achieve specific tumor tissue targeting .

Cat. No.	Product Name	Target	Research Area

HY-P5133

Synstatin (92-119) 1 Publications Verification SSTN92-119	Integrin	Cancer
Synstatin (92-119) is an inhibitor of αvβ3/αvβ5 integrins and IGF1R with anti-angiogenic, anti-proliferative, antioxidant and anti-tumor activities. Synstatin (92-119) competitively blocks the capture of αvβ3/αvβ5 integrins and IGF1R by syndecan-1, disrupts the formation of the syndecan-1 : integrin : IGF1R ternary complex, inhibits integrin activation and talin-mediated signaling pathways, and blocks VEGF-induced angiogenesis. Synstatin (92-119) is applicable to research related to cancer and hepatocellular carcinoma .

HY-P0295

Gly-Arg-Gly-Asp-Ser GRGDS	Integrin	Others
Gly-Arg-Gly-Asp-Ser (GRGDS) is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC₅₀ of ～5 and ～6.5 μM

HY-P2153

Maraciclatide	Integrin	Inflammation/Immunology Cancer
Maraciclatide is a synthetic molecule that binds with high affinity to α_vβ₃ and α_vβ₅ integrins via the RGD peptide. Maraciclatide can be used to detect bone metastasis, breast tumors, vascular disease and rheumatoid arthritis in animal models. Maraciclatide can be studied in research on angiogenesis and inflammation .

HY-P10320

T3 Peptide Tumstatin (69-88), human	PI3K Akt	Cardiovascular Disease
T3 Peptide is an active fragment of tumstatin. T3 Peptide binds integrin α_vβ₃/α_vβ₅, activates the PI3K/Akt/p70S6K signaling pathway, and thus stimulates the proliferation and migration of rat cardiac fibroblasts .

HY-P0295A

Gly-Arg-Gly-Asp-Ser TFA GRGDS TFA	Integrin	Inflammation/Immunology
Gly-Arg-Gly-Asp-Ser (TFA) is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin . Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC₅₀ of ∼5 and ∼6.5 μM .

HY-P10677

HB-3-20	Integrin	Cancer
HB-3-20 leads to degradation of the cell surface integrin α_Vβ₅. Transglutaminase 2 (TG2) has specificity for HB-3-20 (k_cat/K_M=0.16 μM ^-1min ^-1) .

HY-P3335

SU015 DOTA-RGDfK dimer	Integrin Radionuclide-Drug Conjugates (RDCs)	Cardiovascular Disease Cancer
SU015 (DOTA-RGDfK dimer) is a *Integrin* α_vβ₅ and α_vβ₃ antagonist. SU015 exhibits comparable affinity for α_vβ₅ and α_vβ₃, with relatively higher potency and specificity compared to other integrins. SU015 inhibits α_vβ₃-mediated cell adhesion to fibrinogen, α_vβ₃-mediated adhesion of activated platelets to osteopontin, and α_vβ₅-mediated cell adhesion to vitronectin. SU015 shows potent inhibitory effects on FGF2-induced angiogenesis in the CAM model. SU015 carries a linker arm available for radioisotope conjugation, and acts as a target-specific radioreagent when labeled with ⁹⁰Y (i.e., RP697) or ¹⁷⁷Lu (i.e., RP688). SU015 can be used in studies related to tumor metastasis and tumors .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.